Back to Search Start Over

Intermittent high-dose melphalan/prednisone vs continuous low-dose melphalan treatment in multiple myeloma.

Intermittent high-dose melphalan/prednisone vs continuous low-dose melphalan treatment in multiple myeloma.

Authors :
Ahre A
Björkholm M
Mellstedt H
Holm G
Brenning G
Engstedt L
Gahrton G
Hällen J
Johansson B
Johansson SG
Karnström L
Killander A
Lerner R
Lockner D
Lönnqvist B
Simonsson B
Stalfelt AM
Ternstedt B
Wadman B
Source :
European journal of cancer & clinical oncology [Eur J Cancer Clin Oncol] 1983 Apr; Vol. 19 (4), pp. 499-506.
Publication Year :
1983

Abstract

Patients with newly diagnosed multiple myeloma were randomly allotted to an intermittent high-dose melphalan/prednisone (MP) treatment (120 patients) or a continuous low-dose melphalan (M) regimen (99 patients). The median observation time was 59 months (range 33-84). Response to therapy was obtained in 45% of the MP group and 31% of the M group (P less than 0.05). No significant difference in response with regard to clinical stage was noted. Median survival was 36 months in the MP group and 29 months in the M group. Survival was longer in stage I and II myeloma than in the stage III cases, at least in the MP group. The median and 5-yr survival rates in stages I and II were significantly better in the MP than in the M group. Response to therapy was associated with length of survival, median survival being 62 months in responding patients and 20 months in non-responders. The MP and M groups did not differ in this respect.

Details

Language :
English
ISSN :
0277-5379
Volume :
19
Issue :
4
Database :
MEDLINE
Journal :
European journal of cancer & clinical oncology
Publication Type :
Academic Journal
Accession number :
6345174
Full Text :
https://doi.org/10.1016/0277-5379(83)90113-x